Recent Postings to


Worst Pills, Best Pills Newsletter Articles

  View the entire January 2017 issue in PDF format

  • Drugs That Increase the Risk of Falling
    (January 2017)
    Falls remain by far the leading cause of injuries among adults age 65 and older in the U.S. In this article, we identify many of the drugs that can increase your risk of falling and offer advice on how to protect yourself from fall-related injuries.
  • Patient Safety Advocates, Industry Spar Over Off-Label Promotion
    (January 2017)
    Worst Pills, Best Pills News editor Dr. Michael Carome discusses highlights of the debate between the pharmaceutical and medical device industry and patient safety advocates at a recent FDA public hearing regarding the agency’s rules on off-label promotion — the pharmaceutical and medical device industry practice of promoting prod¬ucts for unapproved uses.
  • Many Older Adults Do Not Take Blood Pressure Medications as Prescribed
    (January 2017)
    Keeping high blood pressure under control is essential to preventing long-term complications of hypertension, including cardiovascular disease, stroke and kidney failure. Learn about the steps you can take to boost your adherence to your blood pressure medication treatment.
  • Do Not Use Linaclotide (LINZESS) for Irritable Bowel Syndrome or Constipation
    (January 2017)
    Find out why the risks of linaclotide far exceed its benefits for treating patients with irritable bowel syndrome and constipation, and learn about safer alternative treatments for these conditions.
  • FDA Advisory Committee Split on Black-Box Warning on Varenicline (CHANTIX)
    (January 2017)
    In October 2014, Public Citizen joined four other consumer advocacy and research groups to petition the FDA to strengthen the existing black-box warning on the label of the smoking cessation drug varenicline. Find out why the FDA now is considering moving recklessly in the opposite direction by removing the black-box warning from the label.
  • Questions & Answers
    (January 2017)
    In this month Questions & Answers section, we respond to a reader's question about whether calcium-containing antacids, such as TUMS, for heartburn may increase the risk of adverse cardiovascular events.

  View the entire December 2016 issue in PDF format

  • The Rising Cost of Generic Drugs
    (December 2016)
    The ever-increasing prices for prescription medications are often in the news these days, with some products carrying eye-popping price tags of more than $100,000 per year. Typically the highest prices are for newer, brand-name products. Yet a more surprising pricing story has begun to emerge over the past few years: the rising cost of generic medications.
  • FDA Leadership Ignores Science, Approves Ineffective Drug
    (December 2016)
    Learn why the decision by FDA’s leaders to approve a new medication for a rare muscle disorder, over the strenuous objections of the agency’s scientific experts, threatens to undermine public health.
  • Endocrine Society Recommends Against Routine Use of Compounded Hormones
    (December 2016)
    In this article, we explain why FDA-approved bioidentical hormone medications are preferred over custom-mixed (compounded) products for treating hormone-related disorders.
  • Ropinirole: A Second-Choice Drug for Parkinson’s Disease
    (December 2016)
    In this article, we explore recent research showing that the older drug levodopa-carbidopa has a more favorable benefit-risk balance than ropinirole and other newer dopamine agonists for initial treatment of early Parkinson’s disease.
  • Dangers of Sleep Drug Suvorexant Still Outweigh Minimal Benefits
    (December 2016)
    Find out why Public Citizen’s Health Research Group has designated suvorexant as Do Not Use and what steps you can take to improve your sleep without relying on medications.

  View the entire November 2016 issue in PDF format

  • EpiPen Maker Mylan Becomes Lead Pharma Villain
    (November 2016)
    Worst Pills, Best Pills News editor Dr. Michael Carome discusses how drug manufacturer Mylan assumed the banner of most infamous price gouger among pharmaceutical corporations in the U.S.
  • Adding Aliskiren to an ACE Inhibitor in Heart Failure Harmful, Without Benefit
    (November 2016)
    For many years we have recommended never combining the high blood pressure medications aliskiren and ACE inhibitors. In this article, we review new research showing that this combination of drugs poses unacceptable risks in heart failure patients and provides no additional benefit over an ACE inhibitor alone.
  • Oral Treatments for Hypothyroidism
    (November 2016)
    Not all thyroid hormone replacement medications are the same, and some are not even approved for use in the U.S. Learn which of these medications you should take — and which ones you should not take — to treat hypothyroidism (underactive thyroid).
  • Insulin Glargine (TOUJEO): Do Not Use for Seven Years
    (November 2016)
    TOUJEO is a newer, long-acting, once-daily insulin approved by the Food and Drug Administration for the treatment of Type 1 and Type 2 diabetes in adults. Learn why you should avoid using this drug until at least 2022.
  • News Brief for November 2016
    (November 2016)
    In this month's News Brief section, we report on action taken by the Food and Drug Administration to add important new warnings to the labeling of all opioid and benzodiazepines drugs.
  • Commonly Used Antibiotic Can Cause Serious Psychiatric Side Effects
    (November 2016)
    Find out which commonly used antibiotic can cause psychosis, hallucinations, delirium, mood disorders, sleep disturbances and cognitive impairment.

Additional Information from Public Citizen

Copyright © 2017 Public Citizen's Health Research Group. All rights reserved.